Caroline Hutter

Caroline Hutter

Auto-generated profile, based on publicly available information

Caroline Hutter

St Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Immunity
Verified
Journal Article
Closed access
KKKyongrim Kwon
Kyongrim Kwon
CHCaroline Hutter
Caroline Hutter
QSQiong Sun
Qiong Sun
IBIvan Bilic
Ivan Bilic
ĆCĆesar Cobaleda
Ćesar Cobaleda
MBMeinrad Busslinger
Meinrad Busslinger

9 August 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CTCornelis M. van Tilburg
Cornelis M. van Tilburg
EPElke Pfaff
Elke Pfaff
KPKristian W. Pajtler
Kristian W. Pajtler
KLKarin Langenberg
Karin Langenberg
PFPetra Fiesel
Petra Fiesel
OWOlaf Witt
Olaf Witt
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99–not applicable], compared with 117 days (95% CI, 106–143; P = 0.011) in all other patients. The respective molecular targets were shown to be predictive for matched treatment response and not prognostic surrogates for improved outcome. Hereditary cancer predisposition syndromes were identified in 7.5% of patients, half of which were newly identified through the study. Integrated molecular analyses resulted in a change or refinement of diagnoses in 8.2% of cases. Significance: The pediatric precision oncology INFORM registry prospectively tested a target prioritization algorithm in a real-world, multinational setting and identified subgroups of patients benefiting from matched targeted treatment with improved progression-free survival, refinement of diagnosis, and identification of hereditary cancer predisposition syndromes. See related commentary by Eggermont et al., p. 2677 . This article is highlighted in the In This Issue feature, p. 2659

30 January 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NSNathan Sheffield
Nathan Sheffield
GPGaelle Pierron
Gaelle Pierron
JKJohanna Klughammer
Johanna Klughammer
PDPaul Datlinger
Paul Datlinger
ASAndreas Schönegger
Andreas Schönegger
ETEleni M Tomazou
Eleni M Tomazou

1 May 2002 in Development
Verified
Journal Article
Open access
PDF file
Richard Philip GroseRichard Philip Grose
Richard Philip Grose
CHCaroline Hutter
Caroline Hutter
WBWilhelm Bloch
Wilhelm Bloch
ITIrmgard Thorey
Irmgard Thorey
FWFiona M. Watt
Fiona M. Watt
SWSabine Werner
Sabine Werner
Integrins are ubiquitous transmembrane receptors that play crucial roles in cell-cell and cell-matrix interactions. In this study, we have determined the effects of the loss of β1 integrins in keratinocytes in vitro and during cutaneous wound repair. Flow cytometry of cultured β1-deficient keratinocytes confirmed the absence of β1 integrins and showed downregulation of α6β4 but not of αv integrins. β1-null keratinocytes were characterised by poor adhesion to various substrates, by a reduced proliferation rate and by a strongly impaired migratory capacity. In vivo, the loss of β1 integrins in keratinocytes caused a severe defect in wound healing. β1-null keratinocytes showed impaired migration and were more densely packed in the hyperproliferative epithelium. Surprisingly, their proliferation rate was not reduced in early wounds and even increased in late wounds. The failure in re-epithelialisation resulted in a prolonged inflammatory response, leading to dramatic alterations in the expression of important wound-regulated genes. Ultimately, β1-deficient epidermis did cover the wound bed, but the epithelial architecture was abnormal. These findings demonstrate a crucial role of β1 integrins in keratinocyte migration and wound re-epithelialisation. Movies available on-line

1 November 2019 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JDJean Donadieu
Jean Donadieu
ILIslam Amine LARABI
Islam Amine LARABI
MTMathilde Tardieu
Mathilde Tardieu
JVJohannes Visser
Johannes Visser
CHCaroline Hutter
Caroline Hutter
SHSébastien Héritier
Sébastien Héritier
PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score. RESULTS: LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to 0 ( P < .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) and was associated with a higher risk of reactivation at VMF discontinuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone. CONCLUSION: VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH. Additional studies are needed to find effective maintenance therapy approaches.

30 May 2002 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
SJSam M. Janes
Sam M. Janes
SLSally Lowell
Sally Lowell
CHCaroline Hutter
Caroline Hutter